To determine its potential as a BPH pharmacotherapy, unstimulated sections of human prostate were incubated with increasing concentrations of atosiban, an OXTR antagonist [1, 10, 100 and 300 nM]. This evidence concerns the gene OXTR and benign prostatic hyperplasia.